The GHMP kinase family is a unique class of important enzymes that plays an essential role in many metabolic processes. It contains more than 170 protein members among which are the galactokinase (GALK) and the CMK enzymes. GALK plays a crucial role in galactose processing and is a potential therapeutic target for Classic Galactosemia (OMIM: 230400) [1]. CMK is involved for the non-mevalonate synthesis of isoprenoids precursors and natural products like sterols or ubiquinones which are important to many biological functions [2]. Although the sequence identity between GALK and CMK  is low, the three-dimensional structures and active sites are highly similar [3]. Therefore to determine the validity and selectivity of an active compound observed in the GALK qHTS screen (AID: 1868), a bioluminescent counter-screen targeting bacterial CMK was developed. In addition, because the mevalonate independent synthesis of isoprenoids are more prevalent in opportunistic pathogens such as bacteria [4], CMK is a potential novel therapeutic target where selective inhibitors could be used to  determine potential antibacterial effects. The CMK (provided by Kent Lai) was assayed using ATP and 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME; Echelon, cat# I-M052) as substrates.  Promega Kinase-Glo Plus (cat# V3774) technology was used to detect the residual ATP following kinetic reaction. Briefly, the Kinase-Glo Plus contains Ultra-Glo [5] luciferase and D-luciferin which generates a bioluminescence signal from the remaining ATP. Kinase reactions run with and without the enzyme were use as negative and positive controls together with treatment of Protein Tyrosine Phosphatase CD45 inhibitor (EMD Bioscience cat# 540215) which is observed to weakly inhibit the CMK. Three uL/well of substrate solution (15 uM ATP, 30 uM CDP-ME, 20 mM HEPES pH8.0, 5 mM MgCl2, 40 mM KCl, 1 mM DTT, 0.01% BSA final concentration) was dispensed into 1536-well, assay plates (Greiner, solid white medium-binding plates) with Aurora Discovery BioRAPTR Flying Reagent Dispenser (FRD; Beckton-Dickenson). Compound and control solutions (23 nL) were transferred to the assay plate using the Kalypsys 1536-pin tool. One uL/well enzyme solution (0.25 ug/mL CDP-Me kinase, 20 mM HEPES pH8.0, 5 mM MgCl2, 40 mM KCl, 1 mM DTT, 0.01% BSA final concentration) was then added using the FRD yielding a total kinase reaction volume of 4 uL/ well. After 1 hour of room temperature incubation, 4 uL Kinase-Glo Plus reagent was added for a final assay volume of 8 uL/well. After 1 min, luminescence was detected with the ViewLux plate reader (Perkin Elmer, Waltham, MA) using a 1 sec exposure time and 2x binning settings.
bao:BAO_0000541 "1868" ; # "is counter assay of" -> "1868"
bao:BAO_0000812 "2114" ; # "has summary assay" -> "2114"
bao:BAO_0000210 bao:BAO_0000032 ; # "has assay stage" -> "secondary assay"
bao:BAO_0001070 bao:BAO_0001064 ; # "has alternate target assay" -> "alternate target assay"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000357 ; # "has assay format" -> "single protein format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000294 ; # "has participant" -> "kinase" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_0002005 ; # "is bioassay type of" -> "kinase activity assay"
bao:BAO_0000212 bao:BAO_0000124 ; # "has assay method" -> "enzyme activity measurement method"
bao:BAO_0000212 bao:BAO_0002593 ; # "has assay method" -> "substrate coupled enzyme activity measurement method"
bao:BAO_0000212 bao:BAO_0002594 ; # "has assay method" -> "ATP coupled enzyme activity measurement method"
bao:BAO_0000207 bao:BAO_0000045 ; # "has detection method" -> "luminescence method"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Identification of inhibitors of Human Galactokinase (GALK)" ; # "screening campaign name" -> "Identification of inhibitors of Human Galactokinase (GALK)"
bao:BAO_0002853 "Confirmatory Assay for Inhibitors of Human Galactokinase (GALK): CDP-Me assay counterscreen" ; # "has assay title" -> "Confirmatory Assay for Inhibitors of Human Galactokinase (GALK): CDP-Me assay counterscreen"
bao:BAO_0002854 bao:BAO_0000010 ; # "has bioassay type" -> "functional"
bao:BAO_0002867 bao:BAO_0000516 ; # "has assay footprint" -> "1536 well plate"
bao:BAO_0002863 bao:BAO_0000535 ; # "has concentration throughput" -> "multiple concentration"
bao:BAO_0000109 "25 degree celsius" ; # "has temperature value" -> "25 degree celsius"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "25 degree celsius" ; # "substrate incubation temperature" -> "25 degree celsius"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "1 hour" ; # "substrate incubation time" -> "1 hour"
bao:BAO_0002833 "1 hour" ; # "has incubation time value" -> "1 hour"
bao:BA0_0090012 "Protein Tyrosine Phosphatase CD45 inhibitor" ; # "has participant" -> "Protein Tyrosine Phosphatase CD45 inhibitor"
bao:BAO_0000740 bao:BAO_0000080 ; # "has assay control" -> "positive control"
bao:BA0_0090012 "minus Galactokinase" ; # "has participant" -> "minus Galactokinase"
bao:BAO_0000740 bao:BAO_0000079 ; # "has assay control" -> "negative control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Kent Lai" ; # "material entity assay provider" -> "Kent Lai" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BAO_0002739 bao:BAO_0000776 ; # "has substrate" -> "Adenosine triphosphate"
bao:BAO_0002739 bao:BAO_0000777 ; # "has substrate" -> "CDP-ME" || bao:BAO_0003102 bao:BAO_0002030 ; # "has role" -> "coupled substrate"
bao:BA0_0090012 bao:BAO_0000895 ; # "has participant" -> "DTT" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_63247> ; # "has role" -> "reducing agent"
bao:BA0_0090012 bao:BAO_0000776 ; # "has participant" -> "Adenosine triphosphate" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_25078> ; # "has role" -> "luciferin" || bao:BAO_0003102 bao:BAO_00020143 ; # "has role" -> "substrate"
bao:BA0_0090012 "\"4-diphosphocytidyl-2-C-methyl-D-erythritol kinase, chloroplastic\"" ; # "has participant" -> ""4-diphosphocytidyl-2-C-methyl-D-erythritol kinase, chloroplastic""
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_3702> ; # "has organism" -> "Arabidopsis thaliana"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "O81014" ; # "uniprot ID" -> "O81014"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "3702" ; # "NCBI taxonomy ID" -> "3702"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BAO_0002622 bao:BAO_00020127 ; # "has purity value" -> "purified"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BAO_0000308 bao:BAO_0000678 ; # "has assay kit" -> "Kinase-Glo Plus Luminescent Kinase Assay"
bao:BAO_0000308 bao:BAO_0000248 ; # "has assay kit" -> "assay Kit"
bao:BAO_0000737 bao:BAO_0000303 ; # "has manufacturer" -> "Promega" || bao:BAO_0003102 bao:BAO_0002626 ; # "has role" -> "biologics and screening manufacturer"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0000648 bao:BAO_0000733 ; # "compound library" -> "MLSMR library"
bao:BAO_0002865 bao:BAO_0001046 ; # "uses detection instrument" -> "ViewLux CCD Imager"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0000208 bao:BAO_0000186 ; # "has endpoint" -> "AC50"
bao:BAO_0000337 bao:BAO_0000656 ; # "has percent response" -> "efficacy"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "3" ; # "PubChem TID" -> "3"
bao:BAO_0000182 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has response unit" -> "percent"
bao:BAO_0002787 "23" ; # "has concentration-point number" -> "23"
bao:BAO_0002845 "1" ; # "has repetition point-number" -> "1"
bao:BAO_0000196 bao:BAO_0000091 ; # "has mode of action" -> "inhibition"
bao:BAO_0002864 bao:BAO_0000136 ; # "has repetition throughput" -> "single repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Uma" ; # "Annotated by" -> "Uma"
